IP Library Granted Patent US 7,148,324
Granted Patent B1
US 7,148,324 · App. 09/461,684 · Granted Dec 12, 2006

Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation

Assignee: Dendreon Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,148,324
App. No.
09/461,684
Granted
Dec 12, 2006
Kind
B1
Abstract

Compositions and methods for eliciting an in vivo cytotoxic lymphocyte (CTL) response against a modified soluble protein antigen are disclosed. The modified soluble protein antigen comprises an added peptidic sequence which facilitates entry of the modified antigen into antigen presenting cells (APC).

Claims (4)

1. An antigen composition capable of eliciting an enhanced cytotoxic T cell response in the context of a major histocompatibility complex class I molecule (MHC class I), comprising a soluble protein antigen modified by chemical linkage or fusion to an added peptidic sequence consisting of SEQ ID NO:4, wherein said added peptidic sequence facilitates entry of said antigen into antigen presenting cells (APC).

2. The antigen composition of claim 1 wherein said antigen is specific to a tumor or pathogen.

3. The antigen composition of claim 1 , wherein said one or more added peptidic sequences are covalently linked to said antigen.

4. The antigen composition of claim 1 wherein said antigen composition is a fusion protein produced by translation of a continuous nucleotide coding sequence.

Assignments (9)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042389 FRAME: 505. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Feb 14, 2018
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 046088/0882 →
RELEASE OF SECURITY INTEREST Recorded Jul 5, 2017
From: BARCLAYS BANK PLC
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 043089/0288 →
CHANGE OF NAME Recorded May 3, 2017
From: DENDREON PHARMACEUTICALS, INC.
To: DENDREON PHARMACEUTICALS LLC
Reel/Frame 042389/0505 →
SECURITY AGREEMENT Recorded Jul 27, 2015
From: DENDREON PHARMACEUTICALS, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 036190/0503 →
CHANGE OF NAME Recorded Jul 20, 2015
From: DRONE ACQUISITION SUB INC.
To: DENDREON PHARMACEUTICALS, INC.
Reel/Frame 036136/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2015
From: DENDREON CORPORATION, AND ITS WHOLLY OWNED SUBSIDIARIES, DENDREON HOLDINGS, LLC, DENDREON DISTRIBUTION, LLC, AND DENDREON MANUFACTORING, LLC
To: DRONE ACQUISITION SUB INC.
Reel/Frame 036126/0259 →
RELEASE OF SECURITY INTEREST Recorded Feb 18, 2015
From: GE BUSINESS CAPITAL CORPORATION FORMERLY TRANSAMERICA BUSINESS CAPITAL CORPORATION
To: DENDREON CORPORATION
Reel/Frame 035034/0539 →
SECURITY INTEREST Recorded Aug 7, 2001
From: DENDREON CORPORATION
To: TRANSAMERICA BUSINESS CREDIT CORPORATION
Reel/Frame 012043/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2000
From: LAUS, REINER; HAKIM, ITZHAK; VIDOVIC, DAMIR
To: DENDREON CORPORATION
Reel/Frame 010716/0078 →
Continuity (1)
Provisional Application 6011232400 · Dec 14, 1998